Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that
rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with
anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to
recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer
levels.